Eyenuk Wins Juniper Research’s Digital Health Innovation Award for Best Digital Diagnostics Solution

“We are honored that the EyeArt AI Method was chosen as the ‘Best Electronic Diagnostics Solution’ by Juniper Investigate,” stated Kaushal Solanki, Ph.D., founder and CEO of Eyenuk. “The Eyenuk AI platform is currently being created with the goal of screening each and every eye in the environment for continual and vision-threatening diseases. This recognition furthers our motivation to increasing obtain to fast, on-web-site early ailment detection whilst enhancing accuracy and decreasing fees.”

The regular exam for diabetic retinopathy (DR) screening needs an eye treatment specialist to dilate a patient’s eyes and study the back again of the eyes—an expensive method that demands extensive waits for appointments and retains professionals from concentrating on people who have to have therapy. Even while early DR detection and treatment can reduce the risk of blindness by 95%1, as a lot of as 50% of Us citizens with diabetes do not receive their annual eye test2, building DR the foremost induce of blindness between doing work-age grown ups.

The EyeArt system solves these difficulties by making the detection of DR a lot more obtainable although enhancing performance, accuracy, and charge. For the initially time, fully autonomous, authentic-time DR screening can be performed by non-experts at major treatment techniques, diabetes centers, and other frontline treatment options throughout a patient’s regime business check out with hugely precise outcomes out there in seconds. Optimistic cases are referred to eye care experts, making certain their time is optimized for examining and dealing with complicated conditions. The Food and drug administration-cleared EyeArt AI Method is the most extensively validated AI technological know-how for autonomous DR detection, tested on above 500,000 clients globally with 2 million images gathered in clinical environments.

“Early adopters have explained to us that the EyeArt process is a real medical video game changer, generating authentic-time DR screening attainable at place-of-treatment settings by freeing up eye care experts so they can concentrate on a lot more elaborate medical responsibilities,” reported Frank Cheng, President and Main Business Officer of Eyenuk. “We are enormously happy to be acknowledged by Juniper Analysis as an innovator and disruptor in the market as we proceed to produce products for further disease indications.”

Continually outperforming rivals in impartial head-to-head studies, the significant-doing EyeArt program is now utilized by above 100 corporations throughout the world to enhance affected individual access and well being equity and prevent eyesight reduction because of to DR.

About Eyenuk, Inc. 

Eyenuk, Inc. is a world-wide artificial intelligence (AI) health care know-how and providers firm and the leader in true-world AI Eye Screening™ for autonomous ailment detection and AI Predictive Biomarkers™ for risk evaluation and disease surveillance. Eyenuk is on a mission to monitor every eye in the world to guarantee timely diagnosis of existence- and vision-threatening illnesses, which includes diabetic retinopathy, glaucoma, age-connected macular degeneration, stroke hazard, cardiovascular risk, and Alzheimer’s ailment. Uncover Eyenuk on-line on its website, Twitter, Facebook, and LinkedIn. 

About the EyeArt AI System 

The EyeArt AI System gives thoroughly autonomous diabetic retinopathy (DR) screening, which includes retinal imaging, DR detection primarily based on worldwide medical requirements and instant reporting, in a one place of work take a look at all through a diabetic patient’s common examination. When the patient’s fundus photos have been captured and submitted to the EyeArt AI Method, the DR detection effects are available in a PDF report in fewer than 30 seconds. 

The EyeArt AI Procedure was formulated with funding from the U.S. Nationwide Institutes of Health and fitness (NIH) and is validated by the U.K. Nationwide Wellness Support (NHS). In addition to U.S. Food stuff and Drug Administration (Fda) 510(k) clearance, the EyeArt AI Process has CE marking as a course 2a healthcare machine in the European Union and a Overall health Canada license. It is designed to be General Data Safety Regulation (GDPR) and Overall health Coverage Portability and Accountability Act of 1996 (HIPAA) compliant. 

The EyeArt AI Procedure is reimbursable by government and non-public payors in the U.S. less than the newly produced Classification 1 Existing Procedural Terminology (CPT) code 92229. 

Movie: Discover more about the EyeArt AI Program for Autonomous Detection of Diabetic Retinopathy 

Media Call
Todd Stein
+1 510 417 0612 
[email protected]

Eyenuk, Inc. Get hold of
Frank Cheng, President & CCO
+1 818 835 3585 
[email protected]

References:

  1. https://www.niddk.nih.gov/health-data/diabetes/overview/avoiding-challenges/diabetic-eye-condition  
  2. https://www.cdc.gov/visionhealth/basics/ced/index.html 

Supply Eyenuk

Eyenuk Wins Juniper Research’s Digital Health Innovation Award for Best Digital Diagnostics Solution